Explore news & updates

Automated insulin delivery (AID) is transforming type 1 diabetes care, but many Australians still can't access this life-changing technology. Here's why.

A look at how access to Tzield, the first new therapy for type 1 diabetes (T1D) since insulin, is expanding for more people around the world.

Almost 40 years of pivotal Breakthrough T1D funding, industry investment and powerful government advocacy have culminated in the arrival of the first disease-modifying therapy for T1D.

Find answers to frequently asked questions about Tzield, the first drug approved to treat type 1 diabetes (T1D) since insulin.

Breakthrough T1D’s advocacy program educates politicians across the country about T1D and the issues most important to the community.

Learn about the Eledon trial and why it marks a promising step towards making islet transplants safer and more accessible for people with type 1 diabetes (T1D). 

Breakthrough T1D funds a program where family members of those with type 1 diabetes can be screened for early signs of the condition.

This is the first new therapy approved for T1D in over 100 years, since the discovery of insulin.

Breakthrough T1D has appointed James Bracey to its Board, strengthening its leadership in advancing breakthroughs for type 1 diabetes.

Global experts gathered in Brisbane this April for the Immunology of Diabetes Society (IDS) Congress, sharing the latest breakthroughs in type 1 diabetes (T1D) research. Here are our key highlights.

Breakthrough T1D is investing AUD $1.5m to help scientists access a vital resource to study pancreatic cells from organ donors.

Professor Thomas Kay has received the Breakthrough T1D Luminary Award for his dedication to type 1 diabetes (T1D) research.

Explore key insights from Dr Aaron Kowalski, Global CEO of Breakthrough T1D, following his recent visit to Australia.